New York 2025-2026 Regular Session

New York Assembly Bill A07311

Introduced
3/25/25  
Refer
3/25/25  

Caption

Requires certain health insurance policies and contracts to provide coverage for human leukocyte antigen testing, also referred to as histocompatible locus antigen testing, for A, B, and DR antigens, for utilization in tissue typing for bone marrow testing.

Summary

Bill A07311 amends the New York insurance law to require that all health insurance policies providing hospital, surgical, or medical care coverage must include coverage for human leukocyte antigen (HLA) testing. This testing is crucial for tissue typing in bone marrow transplants, specifically for A, B, and DR antigens. The bill aims to ensure that patients requiring such tests for potential transplants are not financially burdened by the costs associated with these necessary medical procedures.

Impact

The passage of this bill will expand the coverage requirements for health insurance policies in New York, mandating that HLA testing be included in hospital, surgical, or medical care coverage. This change will directly impact insurance providers and policyholders, ensuring that individuals needing bone marrow testing have access to necessary diagnostic services without incurring out-of-pocket expenses. It also sets a precedent for future legislation regarding coverage for specialized medical testing.

Sentiment

The sentiment surrounding Bill A07311 appears to be supportive, as it addresses a critical need for patients requiring bone marrow transplants. However, there may be concerns from insurance companies regarding the potential increase in costs associated with mandated coverage. Overall, discussions indicate a recognition of the importance of HLA testing in improving patient outcomes.

Contention

Notable points of contention may arise from insurance providers who could argue against the financial implications of mandating additional coverage. There may also be discussions regarding the exemption for policies covering employees in multiple states or those subject to collective bargaining, as this could limit the bill's overall impact on certain populations.

Companion Bills

No companion bills found.

Previously Filed As

NY SB78

Public Health – Prostate–Specific Antigen Testing (Protect Our Prostate Act)

NY HB3057

Relating to health benefit plan coverage for chimeric antigen receptor T-cell therapy.

NY HB1112

Require the coverage of biomarker testing in certain health insurance policies.

NY A3117

Requires health insurance coverage for testing for BRCA1 and BRCA2 genes.

NY HB2611

Health insurance; coverage for cancer follow-up testing, report.

NY LD107

An Act to Require Health Insurance Coverage for Biomarker Testing

NY SB464

Requiring insurance coverage for biomarker testing

NY S2247

Requires non-invasive prenatal testing for pregnant persons and health insurance coverage for non-invasive prenatal testing.

NY HB06895

An Act Concerning Health Benefit Review And Requiring Health Insurance Coverage For Biomarker Testing.

NY HB830

Health Insurance - Genetic Testing and Cancer Imaging - Required Coverage

Similar Bills

No similar bills found.